Key Drivers
- Strong quarterly margins
- Negative shareholders' equity
- Substantial long-term debt
AIAI Summary
ESPR has shifted from a binary clinical turnaround to a commercial execution and margin-recovery story where valuation now hinges on converting guideline endorsements and Enbumyst commercialization into repeat scripts, successful manufacturing tech transfers, and sustained free‑cash‑flow rather than late‑stage clinical outcomes. Investors should track consecutive quarters of positive free cash flow, visible margin improvement post‑tech transfer, and declining net debt—failure on any of those execution levers (manufacturing, payer coverage, or integration) would quickly reverse the bullish case.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong quarterly margins
- •Negative shareholders' equity
- •Substantial long-term debt
Esprit's latest quarter shows strong profitability and cash generation but the full year's loss, negative shareholders' equity and sizable long-term debt signal significant balance-sheet and earnings volatility risk. #cash-rich #balance-sheet-risk
Price Behavior
Key Price Behavior Insights:
- •Downtrend momentum
- •Support bounce
- •Elevated volatility
Over the last month the stock shifted into a clear downtrend—last month's 21-day SMA ≈ $2.91 vs last trade $2.55, down roughly 25–30% from the Feb‑20 peak, bounced at $2.44 but must clear $3.30–$3.50 to signal a reversal.
~25–30% decline from late‑February highs with range between $3.48 and $2.44 indicating elevated volatility
Sentiment & News
Key News Insights:
- •Strong revenue
- •Strategic acquisition
- •Guideline endorsement
Esperion reported accelerating revenue growth and guideline support for bempedoic acid while moving to expand its cardiovascular franchise via a $75M Corstasis/Enbumyst acquisition amid mixed EPS reaction.
The deal and guideline wins should drive longer‑term commercial upside, though near‑term stock volatility may persist as investors digest EPS miss and acquisition impact
Similar Companies in Healthcare
Other companies in the same sector with AI ratings